TP53 and pancreatic ductal adenocarcinoma: Here, we investigate the effects of KRAS-targeting therapies on the tumor microenvironment using a library of KrasG12D, p53-mutant, murine pancreatic ductal adenocarcinoma–derived cell lines (KPCY) to leverage immune-oncology combination strategies for long-term tumor efficacy.